Skip to main content
. 2022 Feb 18;15(2):245. doi: 10.3390/ph15020245

Table 1.

18F-labeling of tetrazines developed in this study.

graphic file with name pharmaceuticals-15-00245-i001.jpg
Tetrazine X R RCC (%) *
Low Precursor Amount (3.1 nmol)
RCC (%) *
High Precursor Amount
(9.3 nmol)
HPLC TLC HPLC TLC
3 -COO- -H 0 0 18 ± 8 16 ± 6
5 -CH2COO- -H - b - b - b - b
6 -CH2CONH- -H - b - b - b - b
7 -O- -H 45 ± 6 52 ± 4 53 ± 5 55 ± 4
8 -CH2O- -H 23 ± 4 24 ± 3 26 ± 4 28 ± 3
9 c -CH2NH- -H - d - d - d - d
33 -COO- -2-Pyr 24 ± 3 22 ± 3 27 ± 4 25 ± 5
38 -O- -2-Pyr 20 ± 11 21 ± 8 29 ± 10 28 ± 6
41 -CH2O- -2-Pyr 9 ± 1 8 ± 1 23 ± 3 26 ± 6

a Precursor was not obtained. b No reaction observed. c Precursor protected with trityl. d Precursor decompose during reaction. n.d. = not determined. * Radiochemical conversions (RCC) were calculated for each compound by radio-HPLC and radio-TLCs as recently reported [43]. All results were based on n = 3 experiments.